Dr. Dr. med. univ. (A)

Raphael Johannes

Morscher

2017: Certification by the Educational Commission for Foreign Medical Graduates in the United States of America
2013-2017: PhD Molecular, promotio sub auspiciis praesidentis rei publicae; Research Program in Cancer Metabolism, Paracelsus Medical University Salzburg (Prof. Kofler)
2007-2012: Doctor of Medicine (MD) Paracelsus Medical University Salzburg, Harvard University (Boston) und Universität Zürich

seit 2022: Fellow Pediatric Oncology, Department Onkologie, Hämatologie, Immunologie, Stammzelltransplantation, Somatische Gentherapie, Universitäts-Kinderspital, Zürich (Prof. Bourquin)
2021: Fellow Early Phase Clinical Trials Center, Department of Pediatric Oncology, Gustave Roussy Cancer Campus, Villejuif, France (Prof. Geoerger)

seit 2021: Board Certification in Pediatrics (FMH Pädiatrie)
2018-2020: Resident Pediatrics; University Children’s Hospital Zürich (Prof. Grotzer / Prof. Sennhauser)
2013-2016: Resident Pediatrics; University Children’s Hospital Salzburg, Paracelsus Medical University Salzburg (Prof. Sperl)
2013-2015: Resident Human Genetics; Department of Medical Genetics, Medical University Innsbruck (Prof. Zschocke, Prof. Wimmer and Prof. Tinschert)

seit 2021: Training for Board certification in pediatric Hematology/Oncology (FMH Schwerpunkt)
2017-2018: Post-Doc Institute of Integrative Genomics, Princeton University (Prof. Rabinowitz)
2010-2016: United States Medical Licencing Examination 1, 2 CK and 2 CS

• 2018: SSP/SGP Schweizer Gesellschaft für Pädiatrie Talent Prize 2018
• 2017: Promotio sub auspiciis praesidentis rei publicae (dissertation with presidential honors)
• 2015: Long-Term Research Fellowship Paracelsus Medical University Salzburg
• 2007-2012: Scholar Award of the Dr. Otto-Ender-Studienstiftung

• Swiss Society of Pediatric Hematology and Oncology (SSPHO)
• Schweizerische Pädiatrische Onkologie Gruppe (SPOG)
• Société Internationale d’Oncologie Pédiatrique Europe (SIOP)
• Schweizerische Gesellschaft für Pädiatrie (SGP)

• Cancer metabolism
• MYCN-dependent reprogramming of neuroblastoma metabolism
• mutation induced metabolic vulnerabilities in cancer
• entity specific metabolic reprogramming in pediatric cancers

• seit 2021: Holcim Stiftung Wissen Research Grant
• 2021-2022: Heidi Ras Grant, Forschungszentrum für das Kind (FZK)
• 2021: Kurt- und Senta Hermann Stiftung Research Fellowship

• ORCID
• Google Scholar-ID